Trial Profile
An Open-Label, Single-Dose Study to Investigate the Pharmacokinetics of MK-4618 in Patients With Renal Insufficiency
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 12 May 2022
Price :
$35
*
At a glance
- Drugs Vibegron (Primary)
- Indications Overactive bladder
- Focus Pharmacokinetics
- Sponsors Merck Sharp & Dohme; Merck Sharp & Dohme Corp.
- 07 Feb 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 16 Jan 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 21 Dec 2012 Planned End Date changed from 1 Dec 2012 to 1 Jan 2013 as reported by ClinicalTrials.gov.